Soluble guanylate cyclase: A potential therapeutic target for heart failure

Mihai Gheorghiade, Catherine N. Marti, Hani N. Sabbah, Lothar Roessig, Stephen J. Greene, Michael Böhm, John C Jr. Burnett, Umberto Campia, John G F Cleland, Sean P. Collins, Gregg C. Fonarow, Phillip D. Levy, Marco Metra, Bertram Pitt, Piotr Ponikowski, Naoki Sato, Adriaan A. Voors, Johannes Peter Stasch, Javed Butler

Research output: Contribution to journalArticle

53 Citations (Scopus)

Abstract

The number of annual hospitalizations for heart failure (HF) and the mortality rates among patients hospitalized for HF remains unacceptably high. The search continues for safe and effective agents that improve outcomes when added to standard therapy. The nitric oxide (NO) - soluble guanylate cyclase (sGC) - cyclic guanosine monophosphate (cGMP) pathway serves an important physiologic role in both vascular and non-vascular tissues, including regulation of myocardial and renal function, and is disrupted in the setting of HF, leading to decreased protection against myocardial injury, ventricular remodeling, and the cardio-renal syndrome. The impaired NO-sGC-cGMP pathway signaling in HF is secondary to reduced NO bioavailability and an alteration in the redox state of sGC, making it unresponsive to NO. Accordingly, increasing directly the activity of sGC is an attractive pharmacologic strategy. With the development of two novel classes of drugs, sGC stimulators and sGC activators, the hypothesis that restoration of NO-sGC-cGMP signaling is beneficial in HF patients can now be tested. Characterization of these agents in pre-clinical and clinical studies has begun with investigations suggesting both hemodynamic effects and organ-protective properties independent of hemodynamic changes. The latter could prove valuable in long-term low-dose therapy in HF patients. This review will explain the role of the NO-sGC-cGMP pathway in HF pathophysiology and outcomes, data obtained with sGC stimulators and sGC activators in pre-clinical and clinical studies, and a plan for the further clinical development to study these agents as HF therapy.

Original languageEnglish (US)
Pages (from-to)123-134
Number of pages12
JournalHeart Failure Reviews
Volume18
Issue number2
DOIs
StatePublished - Mar 2013

Fingerprint

Heart Failure
Nitric Oxide
Cyclic GMP
Therapeutics
Cardio-Renal Syndrome
Hemodynamics
Soluble Guanylyl Cyclase
Ventricular Remodeling
Biological Availability
Oxidation-Reduction
Blood Vessels
Hospitalization
Kidney
Mortality
Wounds and Injuries
Pharmaceutical Preparations

Keywords

  • Cyclic guanosine monophosphate
  • Heart failure
  • Pathophysiology
  • Soluble guanylate cyclase
  • Treatment

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Gheorghiade, M., Marti, C. N., Sabbah, H. N., Roessig, L., Greene, S. J., Böhm, M., ... Butler, J. (2013). Soluble guanylate cyclase: A potential therapeutic target for heart failure. Heart Failure Reviews, 18(2), 123-134. https://doi.org/10.1007/s10741-012-9323-1

Soluble guanylate cyclase : A potential therapeutic target for heart failure. / Gheorghiade, Mihai; Marti, Catherine N.; Sabbah, Hani N.; Roessig, Lothar; Greene, Stephen J.; Böhm, Michael; Burnett, John C Jr.; Campia, Umberto; Cleland, John G F; Collins, Sean P.; Fonarow, Gregg C.; Levy, Phillip D.; Metra, Marco; Pitt, Bertram; Ponikowski, Piotr; Sato, Naoki; Voors, Adriaan A.; Stasch, Johannes Peter; Butler, Javed.

In: Heart Failure Reviews, Vol. 18, No. 2, 03.2013, p. 123-134.

Research output: Contribution to journalArticle

Gheorghiade, M, Marti, CN, Sabbah, HN, Roessig, L, Greene, SJ, Böhm, M, Burnett, JCJ, Campia, U, Cleland, JGF, Collins, SP, Fonarow, GC, Levy, PD, Metra, M, Pitt, B, Ponikowski, P, Sato, N, Voors, AA, Stasch, JP & Butler, J 2013, 'Soluble guanylate cyclase: A potential therapeutic target for heart failure', Heart Failure Reviews, vol. 18, no. 2, pp. 123-134. https://doi.org/10.1007/s10741-012-9323-1
Gheorghiade M, Marti CN, Sabbah HN, Roessig L, Greene SJ, Böhm M et al. Soluble guanylate cyclase: A potential therapeutic target for heart failure. Heart Failure Reviews. 2013 Mar;18(2):123-134. https://doi.org/10.1007/s10741-012-9323-1
Gheorghiade, Mihai ; Marti, Catherine N. ; Sabbah, Hani N. ; Roessig, Lothar ; Greene, Stephen J. ; Böhm, Michael ; Burnett, John C Jr. ; Campia, Umberto ; Cleland, John G F ; Collins, Sean P. ; Fonarow, Gregg C. ; Levy, Phillip D. ; Metra, Marco ; Pitt, Bertram ; Ponikowski, Piotr ; Sato, Naoki ; Voors, Adriaan A. ; Stasch, Johannes Peter ; Butler, Javed. / Soluble guanylate cyclase : A potential therapeutic target for heart failure. In: Heart Failure Reviews. 2013 ; Vol. 18, No. 2. pp. 123-134.
@article{39f004beae7147dea2fa620c8d3c5f52,
title = "Soluble guanylate cyclase: A potential therapeutic target for heart failure",
abstract = "The number of annual hospitalizations for heart failure (HF) and the mortality rates among patients hospitalized for HF remains unacceptably high. The search continues for safe and effective agents that improve outcomes when added to standard therapy. The nitric oxide (NO) - soluble guanylate cyclase (sGC) - cyclic guanosine monophosphate (cGMP) pathway serves an important physiologic role in both vascular and non-vascular tissues, including regulation of myocardial and renal function, and is disrupted in the setting of HF, leading to decreased protection against myocardial injury, ventricular remodeling, and the cardio-renal syndrome. The impaired NO-sGC-cGMP pathway signaling in HF is secondary to reduced NO bioavailability and an alteration in the redox state of sGC, making it unresponsive to NO. Accordingly, increasing directly the activity of sGC is an attractive pharmacologic strategy. With the development of two novel classes of drugs, sGC stimulators and sGC activators, the hypothesis that restoration of NO-sGC-cGMP signaling is beneficial in HF patients can now be tested. Characterization of these agents in pre-clinical and clinical studies has begun with investigations suggesting both hemodynamic effects and organ-protective properties independent of hemodynamic changes. The latter could prove valuable in long-term low-dose therapy in HF patients. This review will explain the role of the NO-sGC-cGMP pathway in HF pathophysiology and outcomes, data obtained with sGC stimulators and sGC activators in pre-clinical and clinical studies, and a plan for the further clinical development to study these agents as HF therapy.",
keywords = "Cyclic guanosine monophosphate, Heart failure, Pathophysiology, Soluble guanylate cyclase, Treatment",
author = "Mihai Gheorghiade and Marti, {Catherine N.} and Sabbah, {Hani N.} and Lothar Roessig and Greene, {Stephen J.} and Michael B{\"o}hm and Burnett, {John C Jr.} and Umberto Campia and Cleland, {John G F} and Collins, {Sean P.} and Fonarow, {Gregg C.} and Levy, {Phillip D.} and Marco Metra and Bertram Pitt and Piotr Ponikowski and Naoki Sato and Voors, {Adriaan A.} and Stasch, {Johannes Peter} and Javed Butler",
year = "2013",
month = "3",
doi = "10.1007/s10741-012-9323-1",
language = "English (US)",
volume = "18",
pages = "123--134",
journal = "Heart Failure Reviews",
issn = "1382-4147",
publisher = "Springer Netherlands",
number = "2",

}

TY - JOUR

T1 - Soluble guanylate cyclase

T2 - A potential therapeutic target for heart failure

AU - Gheorghiade, Mihai

AU - Marti, Catherine N.

AU - Sabbah, Hani N.

AU - Roessig, Lothar

AU - Greene, Stephen J.

AU - Böhm, Michael

AU - Burnett, John C Jr.

AU - Campia, Umberto

AU - Cleland, John G F

AU - Collins, Sean P.

AU - Fonarow, Gregg C.

AU - Levy, Phillip D.

AU - Metra, Marco

AU - Pitt, Bertram

AU - Ponikowski, Piotr

AU - Sato, Naoki

AU - Voors, Adriaan A.

AU - Stasch, Johannes Peter

AU - Butler, Javed

PY - 2013/3

Y1 - 2013/3

N2 - The number of annual hospitalizations for heart failure (HF) and the mortality rates among patients hospitalized for HF remains unacceptably high. The search continues for safe and effective agents that improve outcomes when added to standard therapy. The nitric oxide (NO) - soluble guanylate cyclase (sGC) - cyclic guanosine monophosphate (cGMP) pathway serves an important physiologic role in both vascular and non-vascular tissues, including regulation of myocardial and renal function, and is disrupted in the setting of HF, leading to decreased protection against myocardial injury, ventricular remodeling, and the cardio-renal syndrome. The impaired NO-sGC-cGMP pathway signaling in HF is secondary to reduced NO bioavailability and an alteration in the redox state of sGC, making it unresponsive to NO. Accordingly, increasing directly the activity of sGC is an attractive pharmacologic strategy. With the development of two novel classes of drugs, sGC stimulators and sGC activators, the hypothesis that restoration of NO-sGC-cGMP signaling is beneficial in HF patients can now be tested. Characterization of these agents in pre-clinical and clinical studies has begun with investigations suggesting both hemodynamic effects and organ-protective properties independent of hemodynamic changes. The latter could prove valuable in long-term low-dose therapy in HF patients. This review will explain the role of the NO-sGC-cGMP pathway in HF pathophysiology and outcomes, data obtained with sGC stimulators and sGC activators in pre-clinical and clinical studies, and a plan for the further clinical development to study these agents as HF therapy.

AB - The number of annual hospitalizations for heart failure (HF) and the mortality rates among patients hospitalized for HF remains unacceptably high. The search continues for safe and effective agents that improve outcomes when added to standard therapy. The nitric oxide (NO) - soluble guanylate cyclase (sGC) - cyclic guanosine monophosphate (cGMP) pathway serves an important physiologic role in both vascular and non-vascular tissues, including regulation of myocardial and renal function, and is disrupted in the setting of HF, leading to decreased protection against myocardial injury, ventricular remodeling, and the cardio-renal syndrome. The impaired NO-sGC-cGMP pathway signaling in HF is secondary to reduced NO bioavailability and an alteration in the redox state of sGC, making it unresponsive to NO. Accordingly, increasing directly the activity of sGC is an attractive pharmacologic strategy. With the development of two novel classes of drugs, sGC stimulators and sGC activators, the hypothesis that restoration of NO-sGC-cGMP signaling is beneficial in HF patients can now be tested. Characterization of these agents in pre-clinical and clinical studies has begun with investigations suggesting both hemodynamic effects and organ-protective properties independent of hemodynamic changes. The latter could prove valuable in long-term low-dose therapy in HF patients. This review will explain the role of the NO-sGC-cGMP pathway in HF pathophysiology and outcomes, data obtained with sGC stimulators and sGC activators in pre-clinical and clinical studies, and a plan for the further clinical development to study these agents as HF therapy.

KW - Cyclic guanosine monophosphate

KW - Heart failure

KW - Pathophysiology

KW - Soluble guanylate cyclase

KW - Treatment

UR - http://www.scopus.com/inward/record.url?scp=84878222682&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84878222682&partnerID=8YFLogxK

U2 - 10.1007/s10741-012-9323-1

DO - 10.1007/s10741-012-9323-1

M3 - Article

C2 - 22622468

AN - SCOPUS:84878222682

VL - 18

SP - 123

EP - 134

JO - Heart Failure Reviews

JF - Heart Failure Reviews

SN - 1382-4147

IS - 2

ER -